Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is a cholinesterase inhibitor presented as an oral dosage form for systemic use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis and related disorders.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon, a cholinesterase inhibitor, is used in conditions affecting neuromuscular transmission.

Myasthenia gravis: improves muscle strength and reduces fatigue in affected individuals. Congenital myasthenic syndromes: enhances neuromuscular signaling to alleviate weakness. Reversal of non‑depolarizing neuromuscular blockade: accelerates recovery of muscle function after surgery.

Pyridostigmine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation - Muscle cramps - Sweating

Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bradycardia - Bronchospasm - Seizures - Allergic reactions (rash, angioedema) - Cardiac arrhythmias

When prescribing pyridostigmine, clinicians should consider several precautionary measures to ensure safe use.

Respiratory monitoring: assess for signs of respiratory compromise, especially in severe myasthenia gravis. Renal function: adjust dose in patients with impaired renal clearance. Asthma or COPD: use cautiously as bronchospasm may be precipitated. Concurrent anticholinergic drugs: avoid or monitor for reduced efficacy. Electrolyte balance: monitor potassium and magnesium levels to prevent cholinergic excess. Store at room temperature: keep in the original container, protect from moisture and heat.

Pyridostigmine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Anticholinergic agents: diminish therapeutic effect. - Other cholinesterase inhibitors: increase risk of cholinergic crisis. - Aminoglycoside antibiotics: potentiate neuromuscular blockade. - Succinylcholine: may prolong paralysis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may exacerbate bradycardia. - Cardiac glycosides: risk of arrhythmias. - Diuretics: can cause electrolyte disturbances affecting drug action. - Magnesium supplements: may enhance neuromuscular effects.